Stockreport

How Bullish Analyst Coverage and New Capital Raise Could Impact Olema Pharmaceuticals (OLMA) Investors [Yahoo! Finance]

Olema Pharmaceuticals, Inc.  (OLMA) 
PDF the company advances Phase 3 and Phase 1 oncology trials supported by fresh capital from a November 2025 public offering of about US$218.50 million. This cluster of op [Read more]